TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Prolynx Secures $70 Million Series A to Advance Portfolio of Ultra-Long-Acting Obesity Candidates and Appoints Chris Boulton as Chief Executive Officer

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Chris Boulton
Prolynx Secures $70 Million Series A to Advance Portfolio of Ultra-Long-Acting Obesity Candidates and Appoints Chris Boulton as Chief Executive Officer

Biotechnology company Prolynx raised $70 million in Series A funding led by 5AM Ventures, OrbiMed, and Monograph Capital to develop ultra-long-acting obesity treatments with monthly and quarterly dosing capabilities. Chris Boulton was appointed CEO, with founder Daniel Santi transitioning to Chief Technical and Scientific Officer.

Insights
AAPL   positive

Recently reached $4 trillion market cap


AMGN   neutral

Mentioned as previous employer of new CEO, no direct business interaction